UB Paderborn / Katalog / Suche / in CDI

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2018-01, Vol.19 (1), p.87-100

2018

Volltextzugriff (PDF)

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Breast cancer research : BCR, 2018-10, Vol.20 (1), p.120-120, Article 120

2018

Volltextzugriff (PDF)

Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors

Proceedings of the National Academy of Sciences - PNAS, 2002-10, Vol.99 (20), p.12963-12968

2002

Volltextzugriff (PDF)

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Scientific reports, 2021-12, Vol.11 (1), p.23463-23463, Article 23463

2021

Volltextzugriff (PDF)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Clinical cancer research, 2022-11, Vol.28 (21), p.4714-4723

2022

Volltextzugriff (PDF)

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

The New England journal of medicine, 2004-03, Vol.350 (11), p.1081-1092

2004

Volltextzugriff (PDF)

Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development

Genome medicine, 2023-12, Vol.15 (1), p.104-15, Article 104

2023

Volltextzugriff (PDF)

Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis

Gene, 2021-08, Vol.793, p.145747-145747, Article 145747

2021

Volltextzugriff (PDF)

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma

PloS one, 2013-08, Vol.8 (8), p.e72692-e72692

2013

Volltextzugriff (PDF)

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

Clinical cancer research, 2008-10, Vol.14 (19), p.6330-6335

2008

Volltextzugriff (PDF)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer

JAMA oncology, 2022-11, Vol.8 (11), p.1579

2022

Volltextzugriff (PDF)

Intratumoral Estrogen Disposition in Breast Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1790-1801

2010

Volltextzugriff (PDF)

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

BMC cancer, 2017-02, Vol.17 (1), p.97, Article 97

2017

Volltextzugriff (PDF)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R47-R47, Article R47

2012

Volltextzugriff (PDF)

Molecular portraits of human breast tumours

Nature (London), 2000-08, Vol.406 (6797), p.747-752

2000

Volltextzugriff (PDF)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

Genome medicine, 2022-08, Vol.14 (1), p.1-86, Article 86

2022

Volltextzugriff (PDF)

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

NMR in biomedicine, 2012-09, Vol.25 (9), p.1033-1042

2012

Volltextzugriff (PDF)

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation

Clinical cancer research, 2011-08, Vol.17 (15), p.4948-4958

2011

Volltextzugriff (PDF)

APOBEC3A/B deletion polymorphism and endometrial cancer risk

Cancer medicine (Malden, MA), 2023-03, Vol.12 (6), p.6659-6667

2023

Volltextzugriff (PDF)

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

PloS one, 2012-06, Vol.7 (6), p.e38364

2012

Volltextzugriff (PDF)

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

European journal of cancer (1990), 2012-09, Vol.48 (13), p.1988-1996

2012

Volltextzugriff (PDF)

Long-Term Follow-Up of the Intergroup Exemestane Study

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2507-2514

2017

Volltextzugriff (PDF)

Vascular proliferation is a prognostic factor in breast cancer

Breast cancer research and treatment, 2012-06, Vol.133 (2), p.501-510

2012

Volltextzugriff (PDF)

Constitutional Mosaic Epimutations - a hidden cause of cancer?

Cell Stress, 2019-03, Vol.3 (4), p.118-135

2019

Volltextzugriff (PDF)

Assessment of tumor suppressor promoter methylation in healthy individuals

Clinical epigenetics, 2020-08, Vol.12 (1), p.131-131, Article 131

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development

Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer

Intratumoral Estrogen Disposition in Breast Cancer

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Molecular portraits of human breast tumours

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation

APOBEC3A/B deletion polymorphism and endometrial cancer risk

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

Long-Term Follow-Up of the Intergroup Exemestane Study

Vascular proliferation is a prognostic factor in breast cancer

Constitutional Mosaic Epimutations - a hidden cause of cancer?

Assessment of tumor suppressor promoter methylation in healthy individuals

Suchergebnisse filtern